Literature DB >> 17084997

Ethanol oxidation into acetaldehyde by 16 recombinant human cytochrome P450 isoforms: role of CYP2C isoforms in human liver microsomes.

S Hamitouche1, J Poupon, Y Dreano, Y Amet, D Lucas.   

Abstract

The involvement of cytochromes P450 (CYPs) in the oxidation of ethanol into acetaldehyde was investigated by using 16 recombinant human CYP isoforms. Apparent K(m) and V(m) were determined for CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2C8, CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP2J2, CYP3A4 and CYP4A11. All of the tested CYPs, except CYP2A6 and CYP2C18, metabolized ethanol into significant amounts of acetaldehyde and displayed K(m) values around 10mM. The significant correlation found between ethanol oxidation and CYP2E1, CYP3A4 and CYP1A2 catalytic activities in a panel of human liver microsomes confirmed the strong implication of these CYPs in ethanol metabolism. The contribution of CYP2C isoforms which are the most abundant in the liver after CYP3A4, was studied using selective inhibitors either with recombinant CYP2C isoforms or in human liver microsomes. Tienilic acid (100 microM) and ticlopidine (20 microM), mechanism-based inhibitors of CYP2C9 and CYP2C19, respectively, decreased ethanol oxidation by 8+/-1.2% and 7.6+/-1.6% in human liver microsomal samples while selective inhibitors of CYP2E1 (DEDTC 100 microM), CYP3A4 (TAO 50 microM) and CYP1A2 (furafylline 25 microM) decreased it by 11.9+/-2.1%, 19.8+/-1.9% and 16.3+/-3.9%, respectively. As ethanol can be metabolized by most of CYPs, it helps to explain or predict alcohol-xenobiotics interactions which are of high importance in medical prescription.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17084997     DOI: 10.1016/j.toxlet.2006.09.011

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  9 in total

Review 1.  Human Family 1-4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2021-01-18       Impact factor: 5.153

2.  Influence of Ethanol on Darunavir Hepatic Clearance and Intracellular PK/PD in HIV-Infected Monocytes, and CYP3A4-Darunavir Interactions Using Inhibition and in Silico Binding Studies.

Authors:  Narasimha M Midde; Yuqing Gong; Theodore J Cory; Junhao Li; Bernd Meibohm; Weihua Li; Santosh Kumar
Journal:  Pharm Res       Date:  2017-06-14       Impact factor: 4.200

3.  Identification and characterization of sulfonyltransferases catalyzing ethyl sulfate formation and their inhibition by polyphenols.

Authors:  Nicole Stachel; Gisela Skopp
Journal:  Int J Legal Med       Date:  2015-02-14       Impact factor: 2.686

Review 4.  Alcohol consumption effect on antiretroviral therapy and HIV-1 pathogenesis: role of cytochrome P450 isozymes.

Authors:  Santosh Kumar; Mengyao Jin; Anusha Ande; Namita Sinha; Peter S Silverstein; Anil Kumar
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-08-08       Impact factor: 4.481

5.  Butein inhibits ethanol-induced activation of liver stellate cells through TGF-β, NFκB, p38, and JNK signaling pathways and inhibition of oxidative stress.

Authors:  Agnieszka Szuster-Ciesielska; Magdalena Mizerska-Dudka; Jadwiga Daniluk; Martyna Kandefer-Szerszeń
Journal:  J Gastroenterol       Date:  2012-06-22       Impact factor: 7.527

6.  Association of cytochrome P450 2C9 polymorphism with locally advanced head and neck squamous cell carcinoma and response to concurrent cisplatin-based radical chemoradiation.

Authors:  Sayan Paul; Tamojit Chaudhuri; M C Pant; D Parmar; Kirti Srivastava
Journal:  South Asian J Cancer       Date:  2014-07

7.  Association of polymorphism in cytochrome P450 2C9 with susceptibility to head and neck cancer and treatment outcome.

Authors:  Sunishtha S Yadav; Shilpi Seth; Anwar J Khan; Shailendra S Maurya; Ankur Dhawan; Sidharth Pant; Mohan C Pant; Devendra Parmar
Journal:  Appl Transl Genom       Date:  2013-08-27

8.  Telomerase reverse transcriptase mutations in plasma DNA in patients with hepatocellular carcinoma or cirrhosis: Prevalence and risk factors.

Authors:  Jingjing Jiao; Gordon P Watt; Heather L Stevenson; Tiffany L Calderone; Susan P Fisher-Hoch; Yuanqing Ye; Xifeng Wu; John M Vierling; Laura Beretta
Journal:  Hepatol Commun       Date:  2018-04-27

9.  Influence of lifestyle choices on risks of CYP1B1 polymorphisms for prostate cancer.

Authors:  Taku Kato; Yutaka Hashimoto; Ryan K Wong; Yozo Mitsui; Shigekatsu Maekawa; Inik Chang; Varahram Shahryari; Soichiro Yamamura; Shahana Majid; Sharanjot Saini; Z Laura Tabatabai; Rajvir Dahiya; Takashi Deguchi; Yuichiro Tanaka
Journal:  J Cell Mol Med       Date:  2018-08-22       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.